Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Diponegoro Medica Hospitalia
Herniah Asti Wulanjani
Unknown Affiliation
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Hubungan Ratio Trigliserida/HDL-C Dengan HbA1c Pada Penderita Diabetes Melitus Tipe 2 Obed Huger Nainggolan; Herniah Asti Wulanjani
Medica Hospitalia : Journal of Clinical Medicine Vol. 5 No. 1 (2018): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (256.955 KB) | DOI: 10.36408/mhjcm.v5i1.348

Abstract

Latar belakang :Diabetes Melitus tipe 2 meliputi 90% dari semua populasi diabetes. Peningkatan prevalensi diabetes melitus dapatdisertaidengan peningkatan prevalensipenyakit kardiovaskuler. Salah satu faktor risiko terjadinya PJK pada DM tipe 2 adalah dyslipidemia. Dislipidemia adalah gangguan metabolisme lipid, dimana yang paling sering ditemukan adalah peningkatan kadar Trigliserida dan penurunan kadar HDL-C. Penelitianmenunjukan bahwa menurunkan HbA1c dapat menunda ataumencegahkomplikasi kronik. Tujuan : Mengetahui hubungan ratio Trigliserida/HDL-C dengan HbA1c pada penderita DM tipe 2 Metode : Penelitian potong lintang pada rekam medik 59 pasien Diabetes Melitus tipe 2 di RSUP Dr.Kariadi. Kadar Profil Lipid terdiri dari Kolesterol Total, Trigliserida, HDL-C, LDL-C diperiksa dengan metoda kolometrik enzimatik, kadar HbA1c dengan metoda turbidimetri. Hasil : Korelasi ratio Trigliserida /HDL-C dengan kadar HbA1c adalah 0,152 (p = 0,250 yang menandakan bahwa ada hubungan yang positif namun tidak signifikan antara ratio Trigliserida/HDL-C dengan kadar HbA1c. Simpulan: Tidak terdapat hubungan antara ratio Trigliserida /HDL-C dengan kadar HbA1c. Kata kunci : Trigliserida, HDL-C, HbA1c, DM tipe 2
CASE PRESENTATION OF 55-YEAR-OLD MAN WITH ACUTE MYELOID LEUKEMIA AND COVID 19 Novita Fajar Sari; Herniah Asti Wulanjani; Ardhea Jaludamascena; Dwi Retnoningrum
JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL) Vol 11, No 3 (2022): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)
Publisher : Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/dmj.v11i3.33926

Abstract

Background: Acute myeloid leukemia (AML) is a malignancy originating from multipotential hematopoietic cells, which is characterized by clonal proliferation of abnormal blast cells in the bone marrow and failure of normal cell production. Coronavirus disease-19 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. COVID-19 infection in AML patients will affect laboratory examinations to support the diagnosis of COVID-19 and the patient's prognosis. Case presentation: A 55-year- old man went to the hospital for chemotherapy and diagnosed of acute myelomonocytic leukemia. Patient complains of his gingival bleeding. The results of the routine haematological examination showed pancytopenia and the patient requires blood transfusion before chemotherapy. On the third day of treatment, the patient complained of fever, after several day patient complained cough, and shortness of breath. Physical examination showed pulse 100x/minutes, respiratory rate 26x/minutes, temperature 39.8˚C, crackles of the lungs. RT-PCR examination from nasopharyngeal swab showed a positive SARS-CoV-2. During treatment, the laboratory tests showed pancytopenia, increased D-Dimer, C-reactive protein, ferritin and procalcitonin. After the 42th day of treatment, the patient had clinical improvement, the fifth evaluation swab showed a negative RT-PCR result. Conclusion: AML patients have a higher risk of infection, especially COVID-19 infection. Correct laboratory examinations and treatment will promote a better prognosis. It is necessary to educate leukemic patients so that they always take precautions against infection, especially the prevention of COVID-19. 
Co-Authors Ardhea Jaludamascena Dwi Retnoningrum Novita Fajar Sari Obed Huger Nainggolan